Today Nov 10 iShares Nasdaq Biotechnology ETF (IBB) Reduces 2.21%

iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) has negative Nov 10 day. The ETF reached $107.73 per share after 2.21% change. It has 8.18 billion net assets and 1.78% volatility for the month.

During the day 1.60 million shares traded hands, in comparisong to to iShares Nasdaq Biotechnology ETF’s (NASDAQ:IBB) average volume of 2.69M for the last 30 days.

The ATR of ETF is 2.08, that’s -9.74% of its 52-Week High and 14.31% of its 52-Week Low. The current year and quarter performance are: 0.85% and 0.31%.

iShares Nasdaq Biotechnology ETF achieved perf of -2.36% YTD, 1 year of -0.34% and 3 years of -1.15%.

iShares Nasdaq Biotechnology ETF have 14.45 avg P/E ratio, also have 3.53 PB ratio. The price to cashflow ratio is 12.72 and the PS ratio is 4.76. On 02/12/2001 it was started. Amgen Inc is the fund’s main investment for 9.04% of assets, Gilead Sciences Inc for 8.43%, Biogen Inc for 8.06%, Celgene Corp for 6.80%, Illumina Inc for 6.18%, Vertex Pharmaceuticals Inc for 4.30%, Regeneron Pharmaceuticals Inc for 3.91%, Alexion Pharmaceuticals Inc for 3.53%, Biomarin Pharmaceutical Inc for 2.31%, Mylan NV for 2.28%. The current iShares Nasdaq Biotechnology ETF’s yield is 0.21%. With Basic Materials 0.00%, Consumer Cyclical 0.00%, Financial Services 0.00%, Realestate 0.00%, Consumer Defensive 0.06%, Healthcare 99.92%, Utilities 0.00%, Communication Services 0.00%, Energy 0.00%, Industrials 0.00%, Technology 0.02% sector weights.

For more iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) news posted recently go to:,,, or The titles are as follows: “Healthcare And Biotechnology Dashboard – Update” posted on November 06, 2018, “MiMedx stock plunges after receiving delisting notice from Nasdaq” on November 07, 2018, “Sarpeta CEO buys another $2M of company stock” with a publish date: October 31, 2018, “Scary Markets, Frightening Stocks, and How to Keep From Panicking” and the last “7 Rising Healthcare Stocks to Consider” with publication date: October 29, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.